Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	All Solid Tumour	IV	D3-002 A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours	Dr Matthew Ng	NCT02521844	Open
2	Epithelial sarcoma, NPC, Gastric, Prostate Ovarian & DLBCL	IV	CMAK683X2101 A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Dr Daniel Tan	NCT02900651	Open
3	NSCLC	IV	CTNO155X2101 An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors	Dr Daniel Tan	NCT03114319	Open
4	CRC and PDAC	Advanced	CTMT212XSG01T Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma	Dr David Tai	NCT04303403	Open
5	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	CPDR001C2101 Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients	Dr Daniel Tan	NCT03064854	Open
6	All Solid Tumour	documented RET infusion	LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Dr Daniel Tan	NCT03157128	Open
7	All Solid Tumour	documented RET infusion	BLU-667-1101 A Phase 1 Study of the Highly-selective RET inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumours	Dr Daniel Tan	NCT03037385	Open
8	NSCLC, Pancreas and all solid tumors	IV	MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	Dr Justina Lam	NCT02912949	Open
9	All Solid Tumour with documented NTRK fusions	must had prior TRK inhibitor	LOXO-EXT-17005 A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers	Dr Daniel Tan	NCT03215511	Open
10	NSCLC, TNBC, PDAC, RCC, Ovarian, CRC, Prostate	IV	CNZV930X2101 A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies	Dr Koo Si-Lin	NCT03549000	Open
11	All Solid Tumour	with documented ATM loss	BAY 1895344 / 18594 An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas	Dr Daniel Tan	NCT03188965	On hold
12	NSCLC	Advanced recurrent	BI 1200.275 A dose finding study of continuous and intermittent high-dose (HDI) Afatinib (EGFR Tyrosine Kinase Inhibitor) on CNS metastases and leptomeningeal disease (LMD) in patients with advanced refractory EGFR mutation positive non-small cell lung cancer	Dr Daniel Tan	NCT03711422	Closing
13	NSCLC	with documented EGFR Exon 20 insertion mutation	CLN-081-001 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Dr Daniel Tan	NCT04036682	Open
14	NSCLC	with documented KRAS	V941-001 A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Dr Daniel Tan	NCT03948763	Open
15	Prostate	Advanced recurrent	Amgen 20180101 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer	Dr Daniel Tan	NCT03792841	Open
16	All Solid Tumour	documented RET infusion	LIBRETTO-201 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation	Dr Daniel Tan	NCT03906331	Open
17	All Solid Tumour	Advanced recurrent	THOR-707-101 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors	Dr Tira Tan	NCT04009681	On hold
18	Ovarian	Recurrent	ORION-02 / NCC OV-03 / CA209-7WC A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients with Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02)	Dr Jack Chan	NCT04620954	Open
19	Melanoma/NSCLC/ esophageal	IV	NP41300 An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/ Tolerability, Pharmacokinetics and Preliminary Anti Tumor Activity of RO7247669, A PD1-LAG3 Bispecific Antibody, in Patients with Advanced and/or Metastatic Solid Tumors	Dr Darren Lim	NCT04140500	Open
20	All Solid Tumour	Advanced recurrent	TAPISTRY Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	Dr Tira Tan	NCT04589845	Open
21	All Solid Tumour	Advanced recurrent	Amgen 20180143 A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors	Dr Daniel Tan	NCT03853109	Open
22	All Solid Tumour	Advanced recurrent	CJDQ443A12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation	Dr Daniel Tan	NCT04699188	Open
23	NSCLC	Advanced recurrent	DESTINY-Lung03 A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Dr Daniel Tan	NCT04686305	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Bladder	Unresectable or Metastatic Urothelial Cancer	CA209-901 A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer	Dr Ravindran Kanesvaran	NCT03036098	Open
2	Bladder	Neoadjuvant and adjuvant chemotherpay for non-muscle invasive bladder cancer	CA017-078 A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer	Dr Ravindran Kanesvaran	NCT03661320	Open
3	Breast	premenopausal perimenopausal HR+ LABC MBC	CLEE011A3201C A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr Yap Yoon Sim	NCT03839823	Open
4	Breast	Metastatic	BEXMET Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype	Dr Elaine Lim	NCT04664829	Open
5	Breast	Neo adj HER2 Neg ER+ tx naive high risk stage II/III	CA209-7FL A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer	Dr Yap Yoon Sim	NCT0410906	Open
6	Breast	PIK3 CA-Mutant HR+, HER2 - LABC/MBC	WO41554 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC 0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant In Patients with Locally Advanced or Metastatic Pik3ca-Mutant Hormone Receptor-Positive, Her2 Negative Breast Cancer	Dr Yap Yoon Sim	NCT04191499	Open
7	Breast	Adjuvant / Metastatic	TCF20-BRE-01 An open-label, single-institution, dose-determining (Part I) and dose-confirmatory (Part II) study to investigate the optimal dose of Tamoxifen in breast cancer patients harboring different TCF20 rs932376 variant alleles	Dr Elaine Lim	NCT04961632	Open
8	Breast	HER2 Neg ER + , 1st line LABC/MBC	EFC15935-AMEERA-5 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER(+), HER2(-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease	Dr Yap Yoon Sim	NCT04478266	Open
9	Breast	TNBC	WO39391-IMPASSION 030 A Phase III, Multicenter, Randomized, Open-label Study Comparing ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) In Combination With Standard Adjuvant ANTHRACYCLINE/TAXANE-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable TRIPLE-NEGATIVE Breast Cancer	Dr Rebecca Dent	NCT03498716	Open
10	Breast	HER2+ Adj	WO42633-Astefania: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy	Dr Yap Yoon Sim	NCT04873362	Open
11	Breast	HER2 +	DESTINY-Breast05: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy	Dr Tira Tan	NCT04622319	Open
12	Breast	HER2 +	D3614C00001-CAPItello-290: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)	Dr Rebecca Dent	NCT03997123	Open
14	Breast	Mets TNBC	D9670C00001: DESTINY-Breast06: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting	Dr Rebecca Tan	NCT04494425	Open
14	Breast	Mets HER2 +	SGNTUC-016 / HER2CLIMB-02: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)	Dr Tira Tan	NCT03975647	Open
15	Breast	Mets TNBC	MO39193-IMPASSION 132: Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer	Dr Rebecca Dent	NCT03371017	Open
16	Colorectal	Neoadjuvant	OTSP-WoOCRC / MK-3475-886 Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer	Dr Iain Tan	NCT03984578	Open
17	Endometrial	HER 2 recurrent advanced or mets endometrial carcinoma	SYD985.003 A phase II study to compare the safety and efficacy of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-expressing recurrent advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy	Dr Chay Wen Yee	NCT04205630	Open
18	Gynae	Endometrial Ca Newly advanced or recurrent Ca	D9311C00001 (DUO-E) A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer	Dr Soh Lay Tin	NCT04269200	Open
19	Esophageal	Unresectable Locally Advanced, Unresectable Recurrent, Metastatic, 1st line	YO42138 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Tiragolumab In Combination With Paclitaxel And Cisplatin Compared With Paclitaxel And Cisplatin As First-Line Treatment In Patients With Unresectable Locally Advanced, Unresectable Recurrent, Or Metastatic Esophageal Squamous Cell Carcinoma	Dr Matthew Ng	NCT04540211	Open
20	Gastric	Neoadjuvant	INNOVATION INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer (EORTC-1203-GITCG)	Dr Matthew Ng	NCT02205047	Open
21	Gastric/ Gastroesophageal Junction	Metastatic or locally advanced	CP-MGAH22-06 A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer	Dr Matthew Ng	NCT04082364	Open
22	Liver	Adjuvant	WO41535 A Phase III, Multicenter, Randomized, Open-Label Study Of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance As Adjuvant Therapy In Patients With Hepatocellular Carcinoma At High Risk Of Recurrence After Surgical Resection Or Ablation	Dr Toh Han Chong	NCT04102098	Open
23	Liver	Advance/ Metastatic 2nd line	CA224-073 A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors	Dr David Tai	NCT04567615	Open
24	Liver	Neoadjuvant + adjuvant	NCCS-OTSP-HCC1 / MK-3475-750 Longitudinal Immune-phenotyping of Surgically Resected HCC following Neoadjuvant and Adjuvant Treatment with MK – 3475	Dr Toh Han Chong	NCT04224480	Open
25	Liver	Adv 1st line	JS001-027-III-HCC A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)	Dr Joycelyn Lee	NCT04523493	Open
26	Liver	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
27	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	BO29554 A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Dr Daniel Tan	NCT03178552	Open
28	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	MK-3475-495 A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Dr Daniel Tan	NCT03516981	Open
29	Lung	LOCALLY ADVANCED/ METASTATIC - 2nd Line	MS200095-0031 A Phase II single arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy (INSIGHT2)	Dr Daniel Tan	NCT03940703	Open
30	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	TAK-788-3001 A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Dr Tanujaa	NCT04129502	Open
31	Lung	locally advanced or metastatic, 1st line	ATORG-0003 A Single-arm, Open-label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation	Dr Daniel Tan	NCT04027647	Open
32	Lung	Adjuvant stage II-III	MeRmaiD-1 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC	Dr Daniel Tan	NCT04385368	Open
33	Lung	Adjuvant stage II-III	MERMAID-2 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy	Dr Daniel Tan	NCT04642469	Open
34	Lung	LA NSCLC	CA209-73L A Phase 3, Randomized, Open-Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Dr Daniel Tan	NCT04026412	Open
35	Lung	Mets NSCLC	LIBRETTO-431 - J2G-MC-JZJC A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer	Dr Daniel Tan	NCT04194944	Open
36	Lung	Mets NSCLC	HERTHENA-Lung01 A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)	Dr Darren Lim	NCT04619004	Open
37	Lung	Mets NSCLC	TROPION-LUNG01 / DS1062-A-U301 Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations	Dr Amit Jain	NCT04656652	Open
38	Lung	Mets NSCLC	CINC280L12301 - (GEOMETRY-E) A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum – pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior 1st/2nd generation EGFR/TKI or osimertinib therapy and whose tumors are T790M mutation negative and harbor MET amplification	Dr Daniel Tan	NCT04816214	Open
39	Nasopharyngeal	Neoadjuvant / Stage IVA	NEO-SPACE Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer	Dr Darren Lim	NCT03734809	Open
40	Nasopharyngeal	Metastatic or recurrent nasopharyngeal carcinoma No more than 1 line	CA209-796 A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma	Dr Darren Lim	NCT03097939	Open
41	Nasopharyngeal	Metastatic or recurrent nasopharyngeal carcinoma First line	NRG-HN007 An open-label, phase III study of platinum-gemcitabine with or without nivolumab in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma	Dr Darren Lim	NCT04458909	On hold
42	Ovarian	Advanced	EPIK-O: CBYL719K1230 A Phase III, multi-center, randomized, open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer.	Dr Chay Wen Yee	NCT04729387	Open
43	Prostate	Metastatic	CA209-7Dx A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)	Dr Ng Quan Sing	NCT04100018	On hold
44	Prostate	Metastatic	XL184-315 (CONTACT-02) A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer	Dr Ng Quan Sing	NCT04446117	Open
45	Prostate	Metastatic	Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH	Dr Ng Quan Sing	NCT04597125	Open
46	Renal	Resectable Renal Cancer	CA209-914 A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse	Dr Ravindran Kanesvaran	NCT03138512	Open
47	Sarcoma	Recurrent	Radical resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of high risk recurrent retroperitoneal sarcoma	Dr Johnny Ong	NCT03792867	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	CLDK378A2X01B An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	Dr Daniel Tan	NCT02584933	Open
2	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	LOXO-TRK-15002 (NAVIGATE) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors	Dr Daniel Tan	NCT02576431	Open
3	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
4	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 2nd Line Onwards	CNIR178X2201 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma	Dr Daniel Tan	NCT03207867	Open
5	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
6	SOLID TUMORS (currently only HCC and gastric cohorts are opened)	Advanced curatively unresectable solid tumors failing standard therapy. HCC: must have failed at least 1 line of standard therapy Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment) Other solid tumours: must have failed at least 1 line of standard therapy	NCCS-2018-Phase2-PRL3 An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours	Dr Matthew Ng	NCT04118114	Open
7	SOLID TUMORS	Any solid tumors with peritoneal mets	Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases	Dr Claramae Chia	NCT04956068	Open